Physician profile
Dion E Gallant
NPI 1730195439
$2,985.86
in general payments reported to CMS, 2019-2025
22 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $64.84 · 2021: $205 · 2022: $437 · 2023: $444 · 2024: $739 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $430.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $312.03 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $297.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $295.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.13 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $191.12 | 2022-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $181.83 | 2019-2025 | Veozah |
| Lilly USA, LLC | $178.67 | 2020-2025 | Mounjaro, Kisunla, Zepbound |
| Medtronic, INC. | $163.44 | 2023 | Onyx Frontier |
| Janssen Pharmaceuticals, INC | $157.82 | 2019-2024 | Xarelto |
| Abbvie INC. | $123.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $87.51 | 2019-2024 | Gardasil 9, M-M-R II, Gardasil |
| Novartis Pharmaceuticals Corporation | $74.36 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $65.56 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $62.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $38.16 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $30.75 | 2019 | |
| Coopersurgical, INC. | $22.22 | 2025 | Paragard T 380a |
| Kyowa Kirin, INC. | $22.02 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.15 | 2024 | Voquezna |
| Abbott Laboratories | $17.68 | 2023 | Freestyle Libre |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dion Gallant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.